NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

NASDAQ:NKTR • US6402683063

70.37 USD
+1.95 (+2.85%)
At close: Feb 25, 2026
70 USD
-0.37 (-0.53%)
Pre-Market: 2/26/2026, 6:46:22 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall NKTR gets a fundamental rating of 2 out of 10. We evaluated NKTR against 192 industry peers in the Pharmaceuticals industry. NKTR may be in some trouble as it scores bad on both profitability and health. NKTR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • NKTR had negative earnings in the past year.
  • In the past year NKTR has reported a negative cash flow from operations.
  • NKTR had negative earnings in each of the past 5 years.
  • NKTR had a negative operating cash flow in each of the past 5 years.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

  • NKTR has a Return On Assets (-40.07%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -141.90%, NKTR is doing worse than 69.27% of the companies in the same industry.
Industry RankSector Rank
ROA -40.07%
ROE -141.9%
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • NKTR's Gross Margin of 87.26% is amongst the best of the industry. NKTR outperforms 90.10% of its industry peers.
  • In the last couple of years the Gross Margin of NKTR has declined.
  • NKTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NKTR has less shares outstanding
  • The number of shares outstanding for NKTR has been increased compared to 5 years ago.
  • The debt/assets ratio for NKTR is higher compared to a year ago.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • NKTR has an Altman-Z score of -13.76. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
  • NKTR's Altman-Z score of -13.76 is on the low side compared to the rest of the industry. NKTR is outperformed by 77.08% of its industry peers.
  • NKTR has a Debt/Equity ratio of 0.88. This is a neutral value indicating NKTR is somewhat dependend on debt financing.
  • NKTR's Debt to Equity ratio of 0.88 is on the low side compared to the rest of the industry. NKTR is outperformed by 70.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF N/A
Altman-Z -13.76
ROIC/WACCN/A
WACC9.16%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
  • NKTR has a better Current ratio (4.24) than 60.94% of its industry peers.
  • A Quick Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
  • NKTR's Quick ratio of 4.24 is fine compared to the rest of the industry. NKTR outperforms 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.13%, which is quite good.
  • The Revenue for NKTR has decreased by -32.79% in the past year. This is quite bad
  • NKTR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.00% yearly.
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%

3.2 Future

  • Based on estimates for the next years, NKTR will show a decrease in Earnings Per Share. The EPS will decrease by -0.28% on average per year.
  • Based on estimates for the next years, NKTR will show a small growth in Revenue. The Revenue will grow by 3.63% on average per year.
EPS Next Y9.43%
EPS Next 2Y6.75%
EPS Next 3Y-0.17%
EPS Next 5Y-0.28%
Revenue Next Year-56.1%
Revenue Next 2Y-35.01%
Revenue Next 3Y-29.51%
Revenue Next 5Y3.63%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 20 -20 40 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NKTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.75%
EPS Next 3Y-0.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEKTAR THERAPEUTICS

NASDAQ:NKTR (2/25/2026, 8:00:02 PM)

Premarket: 70 -0.37 (-0.53%)

70.37

+1.95 (+2.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners71.23%
Inst Owner Change17.99%
Ins Owners0.84%
Ins Owner Change0.36%
Market Cap1.43B
Revenue(TTM)62.60M
Net Income(TTM)-120.74M
Analysts85.71
Price Target116.72 (65.87%)
Short Float %16.3%
Short Ratio2.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.21%
Min EPS beat(2)4.71%
Max EPS beat(2)31.71%
EPS beat(4)3
Avg EPS beat(4)-0.01%
Min EPS beat(4)-43.22%
Max EPS beat(4)31.71%
EPS beat(8)5
Avg EPS beat(8)-0.46%
EPS beat(12)7
Avg EPS beat(12)-0.71%
EPS beat(16)11
Avg EPS beat(16)4.27%
Revenue beat(2)2
Avg Revenue beat(2)8.01%
Min Revenue beat(2)0.98%
Max Revenue beat(2)15.04%
Revenue beat(4)2
Avg Revenue beat(4)-5.38%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)15.04%
Revenue beat(8)6
Avg Revenue beat(8)13.39%
Revenue beat(12)8
Avg Revenue beat(12)9.53%
Revenue beat(16)9
Avg Revenue beat(16)6.67%
PT rev (1m)0%
PT rev (3m)21.92%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-3.56%
EPS NY rev (1m)0%
EPS NY rev (3m)9.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.86
P/FCF N/A
P/OCF N/A
P/B 16.82
P/tB 16.82
EV/EBITDA N/A
EPS(TTM)-10.82
EYN/A
EPS(NY)-10.07
Fwd EYN/A
FCF(TTM)-9.36
FCFYN/A
OCF(TTM)-9.33
OCFYN/A
SpS3.08
BVpS4.18
TBVpS4.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.07%
ROE -141.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.26%
FCFM N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.4%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -13.76
F-Score3
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
EPS Next Y9.43%
EPS Next 2Y6.75%
EPS Next 3Y-0.17%
EPS Next 5Y-0.28%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%
Revenue Next Year-56.1%
Revenue Next 2Y-35.01%
Revenue Next 3Y-29.51%
Revenue Next 5Y3.63%
EBIT growth 1Y-0.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.36%
EBIT Next 3Y-31.32%
EBIT Next 5YN/A
FCF growth 1Y6.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.67%
OCF growth 3YN/A
OCF growth 5YN/A

NEKTAR THERAPEUTICS / NKTR FAQ

What is the fundamental rating for NKTR stock?

ChartMill assigns a fundamental rating of 2 / 10 to NKTR.


What is the valuation status for NKTR stock?

ChartMill assigns a valuation rating of 0 / 10 to NEKTAR THERAPEUTICS (NKTR). This can be considered as Overvalued.


Can you provide the profitability details for NEKTAR THERAPEUTICS?

NEKTAR THERAPEUTICS (NKTR) has a profitability rating of 1 / 10.